Denosumab-Bbdz 60 mg, 120 mg Suppliers & Bulk Manufacturers

Available Forms: Injection for subcutaneous use

Available Strengths: 60 mg, 120 mg

Reference Brands: Prolia(US & EU); Jubbonti - biosimilar to Prolia

Category: Biosimilars

Jubbonti, a biosimilar to Prolia (denosumab), blocks RANKL, inhibiting osteoclast formation and activity. It effectively treats osteoporosis and prevents bone fractures. Benefits include similar efficacy to Prolia, lower costs, increased access to osteoporosis therapy, and improved bone health and strength when used under medical supervision.

Product Description:

Jubbonti, a biosimilar to Prolia (denosumab), is regulated in the EU and US with dossiers demonstrating biosimilarity, safety, efficacy, and manufacturing quality according to GMP standards. In the US, FDA approval involves extensive comparability, clinical validation, and safety data. In the EU, CE marking certifies conformity with MDR standards for biosimilars. These biosimilars undergo validation, stability testing, and audits, supported by comprehensive documentation including biosimilarity data, clinical trial results, safety profiles, and manufacturing practices. For licensing procedures, approved dossiers, and regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to affordable, high-quality denosumab biosimilars supporting osteoporosis and bone metastasis treatment worldwide.